Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Sorbye, Sveinung W ^a,b   Kilvaer, Thomas K ^b   Valkov, Andrej ^a,b   Donnem, Tom ^a,b   Smeland, Eivind ^c   Al Shibli, Khalid ^b,c   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

CD57; DSS; Ki67; Macrophages; Malignancy grade; NK cells; Soft tissue sarcomas; STS; TGF beta; TMA

Indexed keywords

CD57 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CELL PROLIFERATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; TISSUE MICROARRAY;

EID: 84860371909     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-7     Document Type: Article

References (46)

1. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Gustafson P, Acta Orthop Scand Suppl 1994 259 1 31 8042499 (Pubitemid 24227011)
2. Cancer statistics, 2009. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
3. Surgical margin and its influence on survival in soft tissue sarcoma. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, et al. ANZ J Surg 2006 76 104 109 10.1111/j.1445-2197.2006.03615.x 16626341 (Pubitemid 43363007)
4. The outcomes and prognostic factors of patients with soft-tissue sarcoma. Kiatisevi P, Asavamongkolkul A, Phimolsarnti R, Waikakul S, Benjarassamerote S, J Med Assoc Thai 2006 89 334 342 16696417
5. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Koea JB, Leung D, Lewis JJ, Brennan MF, Ann Surg Oncol 2003 10 432 440 10.1245/ASO.2003.05.014 12734093 (Pubitemid 40486942)
6. Retroperitoneal soft tissue sarcoma. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG, Cancer 2005 104 669 675 10.1002/cncr.21264 16003776 (Pubitemid 41113665)
7. Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. a report from the Intergroup Rhabdomyosarcoma Study I. Raney RB, Crist WM, Maurer HM, Foulkes MA, Cancer 1983 52 44 50 6850544 (Pubitemid 13057606)
8. High graDe soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis. Yang RS, Lane JM, Eilber FR, Dorey FJ, al Shaikh R, Schumacher LY, et al. Cancer 1995 76 1398 1405 10.1002/1097-0142(19951015)76:8<1398::AID-CNCR2820760815>3.0.CO;2-B 8620414
9. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Int J Radiat Oncol Biol Phys 2003 57 739 747 10.1016/S0360-3016(03)00714-4 14529779 (Pubitemid 37194300)
10. Biological prognostic factors in adult soft tissue sarcomas. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, et al. Anticancer Res 2005 25 4519 4526 16334136 (Pubitemid 41729506)
11. The development of immunotherapies for non-small cell lung cancer. Salgaller ML, Expert Opin Biol Ther 2002 2 265 278 10.1517/14712598.2.3.265 11890866 (Pubitemid 34464808)
12. Paradoxical roles of the immune system during cancer development. De Visser KE, Eichten A, Coussens LM, Nat Rev Cancer 2006 6 24 37 10.1038/nrc1782 16397525 (Pubitemid 43053650)
13. NKT cells-conductors of tumor immunity? Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI, Curr Opin Immunol 2002 14 165 171 10.1016/S0952-7915(02)00316-3 11869887 (Pubitemid 34188474)
14. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. Cancer 1997 79 2320 2328 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P 9191519 (Pubitemid 27251014)
15. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Cancer 2000 88 577 583 10.1002/(SICI)1097-0142(20000201)88:3<577::AID- CNCR13>3.0.CO;2-V 10649250 (Pubitemid 30056932)
16. The Accumulation and Prognosis Value of Tumor Infiltrating IL-17 Producing Cells in Esophageal Squamous Cell Carcinoma. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, et al. PLoS One 2011 6 18219 10.1371/journal.pone.0018219 21483813
17. Natural killer cells and cancer. Wu J, Lanier LL, Adv Cancer Res 2003 90 127 156 14710949 (Pubitemid 37549223)
18. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Zhang T, Sentman CL, Cancer Res 2011 71 2066 2076 10.1158/0008-5472.CAN-10-3200 21282338
19. Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Arshad H, Ahmad Z, Hasan SH, Asian Pac J Cancer Prev 2010 11 1637 1640 21338209
20. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH, Int J Clin Exp Pathol 2011 4 444 453 21738816
21. p16 and pRb immunohistochemical expression increases with increasing tumour graDe in mammary phyllodes tumours. Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, et al. Histopathology 2010 56 868 875 10.1111/j.1365-2559.2010.03562.x 20497245
22. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma. Takeshita A, Kimura W, Hirai I, Takasu N, Moriya T, Tezuka K, Watanabe T, Pancreas 2012 41 1 114 20 10.1097/MPA.0b013e318220c1fa 22143341
23. Correlation of Ki-67 and MCM-2 proliferative marker expression with graDe of histological malignancy (G) in ductal breast cancers. Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M, Dziegiel P, Folia Histochem Cytobiol 2010 48 442 446 10.2478/v10042-010-0069-0 21097442
24. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, et al. Int J Cancer 2011 128 1139 1150 10.1002/ijc.25424 20473914
25. Prognostic impact of lymphocytes in soft tissue sarcomas. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. PLoS One 2011 6 14611 10.1371/journal.pone.0014611 21298041
26. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. BMC Clin Pathol 2012 12 5 10.1186/1472-6890-12-5 22375962
27. Expression of M-CSF and CSF-1R is correlated with histological graDe in soft tissue tumors. Richardsen E, Sorbye SW, Crowe JP, Yang JL, Busund LT, Anticancer Res 2009 29 3861 3866 19846920
28. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, et al. J Clin Oncol 2002 20 2417 2428 10.1200/JCO.2002.08.159 12011119 (Pubitemid 34525727)
29. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Donnem T, Al Saad S, Al Shibli K, Delghandi MP, Persson M, Nilsen MN, et al. Clin Cancer Res 2007 13 6649 6657 10.1158/1078-0432.CCR-07-0414 18006765 (Pubitemid 350206800)
30. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Nocito A, Kononen J, Kallioniemi OP, Sauter G, Int J Cancer 2001 94 1 5 10.1002/ijc.1385 11668471 (Pubitemid 32801745)
31. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al. Lung Cancer 2002 35 23 28 10.1016/S0169-5002(01)00292-6 11750709 (Pubitemid 34028087)
32. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. Takanami I, Takeuchi K, Giga M, J Thorac Cardiovasc Surg 2001 121 1058 1063 10.1067/mtc.2001.113026 11385371
33. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Al Shibli K, Al Saad S, Donnem T, Persson M, Bremnes RM, Busund LT, Histopathology 2009 55 301 312 10.1111/j.1365-2559.2009.03379.x 19723145
34. CD57+ T lymphocytes and functional immune deficiency. Focosi D, Bestagno M, Burrone O, Petrini M, J Leukoc Biol 2010 87 107 116 10.1189/jlb.0809566 19880576
35. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. Blood 2010 116 3865 3874 10.1182/blood-2010-04-282301 20733159
36. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N, Br J Cancer 1999 79 40 46 10.1038/sj.bjc.6690009 10408691 (Pubitemid 28566924)
37. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, et al. M-. Oncology 2006 70 115 125 10.1159/000093002 (Pubitemid 43760337)
38. Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Yagiz K, Rittling SR, Exp Cell Res 2009 315 2442 2452 10.1016/j.yexcr.2009.05.002 19427849
39. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. Kirma N, Hammes LS, Liu YG, Nair HB, Valente PT, Kumar S, et al. Cancer Res 2007 67 1918 1926 10.1158/0008-5472.CAN-06-1991 17332318 (Pubitemid 46424207)
40. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. Nat Cell Biol 2009 11 943 950 10.1038/ncb1905 19597490
41. TGFbeta in Cancer. Massague J, Cell 2008 134 215 230 10.1016/j.cell.2008. 07.001 18662538 (Pubitemid 352010335)
42. The prognostic impact of TGF-beta1, fascin. Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, et al. NF-kappaB and PKC-zeta expression in soft tissue sarcomas. PLoS One 2011 6 17507
43. Macrophage colony-stimulating factor (CSF-1) induces pro-inflammatory gene expression and enhances antimicrobial responses of goldfish (Carassius auratus L.) macrophages. Grayfer L, Hanington PC, Belosevic M, Fish Shellfish Immunol 2009 26 406 413 10.1016/j.fsi.2008.12.001 19130890
44. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, et al. Clin Cancer Res 2011 17 183 192 10.1158/1078-0432.CCR-10-2195 21208907
45. Penile fracture repair: assessment of early results and complications using color Doppler ultrasound. Gontero P, Sidhu PS, Muir GH, Int J Impot Res 2000 12 125 128 10.1038/sj.ijir.3900510 11052641
46. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. Bremnes RM, Donnem T, Al Saad S, Al Shibli K, Andersen S, Sirera R, et al. J Thorac Oncol 2011 6 209 217 10.1097/JTO.0b013e3181f8a1bd 21107292